Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Other Operating Expenses (2022 - 2024)

Summit Therapeutics (SMMT) has disclosed Other Operating Expenses for 3 consecutive years, with $205000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Other Operating Expenses rose 14.53% year-over-year to $205000.0, compared with a TTM value of $205000.0 through Sep 2025, down 28.57%, and an annual FY2024 reading of $313000.0, down 68.73% over the prior year.
  • Other Operating Expenses was $205000.0 for Q4 2024 at Summit Therapeutics, up from -$264000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $5.5 million in Q3 2022 and bottomed at -$264000.0 in Q3 2024.
  • Average Other Operating Expenses over 3 years is $752888.9, with a median of $205000.0 recorded in 2024.
  • Peak annual rise in Other Operating Expenses hit 688.89% in 2024, while the deepest fall reached 199.62% in 2024.
  • Year by year, Other Operating Expenses stood at $5.5 million in 2022, then plummeted by 96.72% to $179000.0 in 2023, then rose by 14.53% to $205000.0 in 2024.
  • Business Quant data shows Other Operating Expenses for SMMT at $205000.0 in Q4 2024, -$264000.0 in Q3 2024, and $159000.0 in Q2 2024.